Harrow Health
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing...
Latest News
23 hours ago · seekingalpha.com
Harrow: Strong Revenue Growth And Operating Leverage AheadHarrow Inc. is positioned to achieve its ambitious $350MM 2026 revenue target after strong Q3 execution. VEVYE and IHEEZO delivered robust sequential growth, with VEVYE up 35% and IHEEZO up 62% quarter-over-quarter. Expanded commercial coverage and a larger sales team are driving improved VEVYE ASP and market share gains.
4 days ago · globenewswire.com
Harrow to Participate in Two Investor Conferences in NovemberNASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November: Craig-Hallum 17 th Annual Alpha Select Conference Format: 1x1 investor meetings Date: Tuesday, November 17, 2026 Location: New York, NY 2026 Jefferies Global Healthcare Conference Format: Presentation and 1x1 investor meetings Date/Time: Wednesday, November 18, 2026 at 8:00 a.m.
6 days ago · seekingalpha.com
Harrow, Inc. (HROW) Q3 2026 Earnings Call TranscriptHarrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, CFO & Chief Accounting Officer Patrick Sullivan - Chief Commercial Officer Amir Shojaei - Chief Scientific Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Thomas Shrader - BTIG, LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Mayank Mamtani - B.
6 days ago · marketbeat.com
Harrow Q3 Earnings Call HighlightsHarrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated spending weighed on profitability.
7 days ago · zacks.com
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
7 days ago · zacks.com
Harrow (HROW) Q3 Earnings Lag EstimatesHarrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
7 days ago · globenewswire.com
Harrow Announces Third Quarter 2026 Financial ResultsThird Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenue GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025 Adjusted EBITDA (a non-GAAP measure) of $21.2 million, compared with $(1.2) million in the second quarter of 2026 and $22.8 million in the third quarter of 2025 Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, including fourth quarter Adjusted EBITDA of more than $33 million, compared with prior Adjusted EBITDA guidance of $80 million to $100 million Cash and cash equivalents of $75.3 million as of September 30, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
15 days ago · zacks.com
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
15 days ago · globenewswire.com
Harrow Launches HarrowRx PlatformNASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
19 days ago · seekingalpha.com
Harrow's Top Two Drugs Alone Can Justify Its Current ValuationHarrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated markets and are positioned for significant growth as coverage expands and pricing stabilizes. Temporary headwinds, including inventory dynamics and coverage transitions, have obscured accelerating prescription trends and pricing tailwinds expected to materialize in H2 and beyond.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove HROW